Publications
September 30, 2022
Potential of PVRIG and TIGIT blockade in addressing immunotherapy resistance
Eran Ophir, Immuno UK, London, UK, 30 September 2022
June 28, 2022
PVRIG and TIGIT immune checkpoint blockade in cancer: Emerging translational data from clinical trials
Pierre Ferré, AIS 2022 Montpellier, France, 28 June 2022
April 11, 2022
Poster: The Expression of the PVRIG/TIGIT Pathway is Dominant in the Bone Marrow of Patients with Multiple Myeloma
Masha Frenkel et al, AACR annual meeting, April 08-13, 2022
March 9, 2022
Abstract: The Expression of the PVRIG/TIGIT Pathway is Dominant in the Bone Marrow of Patients with Multiple Myeloma
Masha Frenkel et al, AACR annual meeting, April 08-13, 2022
December 9, 2021
Harnessing PVRIG & TIGIT Combination in Anti-Cancer Immunity
Eran Ophir, VP Research & Drug Discovery, TIGIT Therapies Digital Summit
November 12, 2021
COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab – preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors
Ecaterina Elena Dumbrava, et al, SITC 2021 annual meeting
November 12, 2021
COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab – preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors (video)
Ecaterina Elena Dumbrava, et al, SITC 2021 annual meeting
November 12, 2021
COM902 (Anti-TIGIT antibody) monotherapy – preliminary evaluation of safety, tolerability, pharmacokinetics and receptor occupancy in patients with advanced solid tumors
Ecaterina Elena Dumbrava, et al, SITC 2021 annual meeting
November 12, 2021
COM902 (Anti-TIGIT antibody) monotherapy – preliminary evaluation of safety, tolerability, pharmacokinetics and receptor occupancy in patients with advanced solid tumors (video)
Ecaterina Elena Dumbrava, et al, SITC 2021 annual meeting
June 29, 2021
The TIGIT Pathway, PVRIG, a Novel Pathway Member, Targets for Cancer Immunotherapy: A Deep Dive
Eran Ophir, VP Research and Drug Discover June 2021.
